Baidu
map

Arch Gynecol Obstet:氨氯地平能改善PCOS患者的卵巢血流,增加受孕几率

2020-10-02 MedSci原创 MedSci原创

本研究旨在探究氨氯地平是否能增加排卵前卵泡血流量,从而增强排卵能力,为PCOS女性创造更好的受孕机会,研究结果已在线发表于Arch Gynecol Obstet。

本研究旨在探究氨氯地平是否能增加排卵前卵泡血流量,从而增强排卵能力,为PCOS女性创造更好的受孕机会,研究结果已在线发表于Arch Gynecol Obstet。

 

研究共筛选了165名女性,其中124名女性符合条件,将其平均随机分为62名接受枸橼酸氯米芬和氨氯地平,62名接受枸橼酸氯米芬和安慰剂。主要结果是通过药物给药,通过卵巢动脉的颜色和功率多普勒脉动指数研究氨氯地平是否可以改善排卵前卵泡血流量。次要结果是子宫内膜厚度和临床妊娠情况。

 

结果显示,与安慰剂组相比,氨氯地平组卵巢动脉脉动指数均值显著降低(分别为1.36和1.82,P值为0.002)。两组所有女性在检测到成熟卵泡当日的平均子宫内膜厚度,氨氯地平组明显高于安慰剂组(分别为8.99和7.0,P值为0.003),氨氯地平组临床妊娠率较安慰剂组由11%上升至37%。

 

综上所述,该研究结果表明,氨氯地平能改善卵巢血流,增加受孕几率。

 

原始出处:

 

Haitham A TorkyAtef Shata, et al., Effect of amlodipine on blood flow of preovulatory follicle in women with clomiphene resistant polycystic ovaries: a randomized controlled trial. Arch Gynecol Obstet. 2020 Mar;301(3):845-850. doi: 10.1007/s00404-020-05471-z. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044161, encodeId=082920441613f, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Apr 14 04:02:31 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677797, encodeId=f9fb16e77979a, content=<a href='/topic/show?id=02723804379' target=_blank style='color:#2F92EE;'>#受孕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38043, encryptionId=02723804379, topicName=受孕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=795f27597722, createdName=楚秀娟, createdTime=Sat Feb 06 06:02:31 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011437, encodeId=b169201143eb6, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jun 21 04:02:31 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890323, encodeId=fc2389032384, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 06 08:08:25 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341287, encodeId=bb6c134128e25, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Oct 03 16:02:31 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889636, encodeId=9db788963685, content=学习使人进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200815/e88443dd27a34f178be461d4344819e6/17ff657b2e6e4328a67c4b47269fa6ff.jpg, createdBy=79995409528, createdName=ms7000000127904807, createdTime=Fri Oct 02 01:14:56 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044161, encodeId=082920441613f, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Apr 14 04:02:31 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677797, encodeId=f9fb16e77979a, content=<a href='/topic/show?id=02723804379' target=_blank style='color:#2F92EE;'>#受孕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38043, encryptionId=02723804379, topicName=受孕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=795f27597722, createdName=楚秀娟, createdTime=Sat Feb 06 06:02:31 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011437, encodeId=b169201143eb6, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jun 21 04:02:31 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890323, encodeId=fc2389032384, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 06 08:08:25 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341287, encodeId=bb6c134128e25, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Oct 03 16:02:31 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889636, encodeId=9db788963685, content=学习使人进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200815/e88443dd27a34f178be461d4344819e6/17ff657b2e6e4328a67c4b47269fa6ff.jpg, createdBy=79995409528, createdName=ms7000000127904807, createdTime=Fri Oct 02 01:14:56 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
    2021-02-06 楚秀娟
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044161, encodeId=082920441613f, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Apr 14 04:02:31 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677797, encodeId=f9fb16e77979a, content=<a href='/topic/show?id=02723804379' target=_blank style='color:#2F92EE;'>#受孕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38043, encryptionId=02723804379, topicName=受孕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=795f27597722, createdName=楚秀娟, createdTime=Sat Feb 06 06:02:31 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011437, encodeId=b169201143eb6, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jun 21 04:02:31 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890323, encodeId=fc2389032384, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 06 08:08:25 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341287, encodeId=bb6c134128e25, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Oct 03 16:02:31 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889636, encodeId=9db788963685, content=学习使人进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200815/e88443dd27a34f178be461d4344819e6/17ff657b2e6e4328a67c4b47269fa6ff.jpg, createdBy=79995409528, createdName=ms7000000127904807, createdTime=Fri Oct 02 01:14:56 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
    2021-06-21 zhouqu_8
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044161, encodeId=082920441613f, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Apr 14 04:02:31 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677797, encodeId=f9fb16e77979a, content=<a href='/topic/show?id=02723804379' target=_blank style='color:#2F92EE;'>#受孕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38043, encryptionId=02723804379, topicName=受孕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=795f27597722, createdName=楚秀娟, createdTime=Sat Feb 06 06:02:31 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011437, encodeId=b169201143eb6, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jun 21 04:02:31 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890323, encodeId=fc2389032384, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 06 08:08:25 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341287, encodeId=bb6c134128e25, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Oct 03 16:02:31 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889636, encodeId=9db788963685, content=学习使人进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200815/e88443dd27a34f178be461d4344819e6/17ff657b2e6e4328a67c4b47269fa6ff.jpg, createdBy=79995409528, createdName=ms7000000127904807, createdTime=Fri Oct 02 01:14:56 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
    2020-10-06 1581f8c42cm

    多学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2044161, encodeId=082920441613f, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Apr 14 04:02:31 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677797, encodeId=f9fb16e77979a, content=<a href='/topic/show?id=02723804379' target=_blank style='color:#2F92EE;'>#受孕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38043, encryptionId=02723804379, topicName=受孕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=795f27597722, createdName=楚秀娟, createdTime=Sat Feb 06 06:02:31 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011437, encodeId=b169201143eb6, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jun 21 04:02:31 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890323, encodeId=fc2389032384, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 06 08:08:25 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341287, encodeId=bb6c134128e25, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Oct 03 16:02:31 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889636, encodeId=9db788963685, content=学习使人进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200815/e88443dd27a34f178be461d4344819e6/17ff657b2e6e4328a67c4b47269fa6ff.jpg, createdBy=79995409528, createdName=ms7000000127904807, createdTime=Fri Oct 02 01:14:56 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2044161, encodeId=082920441613f, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Apr 14 04:02:31 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677797, encodeId=f9fb16e77979a, content=<a href='/topic/show?id=02723804379' target=_blank style='color:#2F92EE;'>#受孕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38043, encryptionId=02723804379, topicName=受孕)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=795f27597722, createdName=楚秀娟, createdTime=Sat Feb 06 06:02:31 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011437, encodeId=b169201143eb6, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jun 21 04:02:31 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890323, encodeId=fc2389032384, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200814/81d08245657a4a7f9a1ef713c0ec5878/ec4b201a22194a319b1aeb171bc6bb3d.jpg, createdBy=41e02111625, createdName=1581f8c42cm, createdTime=Tue Oct 06 08:08:25 CST 2020, time=2020-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341287, encodeId=bb6c134128e25, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Oct 03 16:02:31 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889636, encodeId=9db788963685, content=学习使人进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200815/e88443dd27a34f178be461d4344819e6/17ff657b2e6e4328a67c4b47269fa6ff.jpg, createdBy=79995409528, createdName=ms7000000127904807, createdTime=Fri Oct 02 01:14:56 CST 2020, time=2020-10-02, status=1, ipAttribution=)]
    2020-10-02 ms7000000127904807

    学习使人进步

    0

相关资讯

警惕:氨氯地平与这3种他汀的相互作用

在临床上,氨氯地平与他汀类药物合用非常广泛。许多医生和药师认为氨氯地平较安全,与他汀类降脂药不存在相互作用。但研究证明,氨氯地平与辛伐他汀和洛伐他汀合用时具有明显的相互作用,与阿托伐他汀合用时也可能会发生横纹肌溶解症。

J Periodontal Res:氨氯地平诱导的牙龈增生中白细胞介素-17A表达上调

氨氯地平为钙离子通道阻断剂衍生物,是高血压患者常用药物。研究发现,它可诱导牙龈增生。然而,其潜在的机制还未可知。白细胞介素-17A (IL-17A)是一种促炎症因子,近来研究显示,它在纤维化障碍以及上

Am J Kidney Dis:肾移植受者:氯噻酮VS氨氯地平哪个效果更好?

2017年6月,发表在《Am J Kidney Dis》的一项由荷兰科学家进行的研究,得出了氯噻酮与氨氯地平对于他克莫司治疗的肾移植受者降压等效的结论。

降压药分子长效钙拮抗剂都包含哪些药?

降压药分子长效钙拮抗剂都包含哪些药?包含氨氯地片、拉西地平、乐卡地片等。

Neurology:氨氯地平反应性三叉神经痛——病例报道

氨氯地平减轻三叉神经痛的机制:电压门控钙通道能够减轻血管迂曲,以及N型通道(交感调节/镇痛作用)的作用。

临床应该重视氨氯地平与辛伐他汀的相互作用

辛伐他汀在体内依赖细胞色素P450酶中的CYP3A4代谢,氨氯地平能够抑制CYP3A4而减慢辛伐他汀的代谢,导致辛伐他汀血药浓度升高,增加了肌病发生风险。

Baidu
map
Baidu
map
Baidu
map